NCT05335993 2026-04-03A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.CanariaBio Inc.Phase 2 Active not recruiting10 enrolled
NCT05198804 2026-03-18A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncPhase 1/2 Completed117 enrolled
NCT05126342 2025-04-06Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPiAGO Research GmbHPhase 2 Withdrawn
NCT03759600 2024-07-16Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian CancerTakedaPhase 2 Completed20 enrolled 42 charts
NCT03759587 2024-06-07Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian CancerTakedaPhase 2 Completed19 enrolled 39 charts